Media that empowers working people – that's how we build a More Perfect Union.

Don't Miss a Video!

Access our exclusive reporting and rapid response actions directly in your inbox, so you don’t miss a beat in the fight for working people nationwide.

Be a part of a community backing up independent journalism with action.

Ideas

Have a story to tell or idea to share?
Email [email protected]
© 2021 More Perfect Union Action

Together we can build power for working people.

We’re asking questions that really matter, and telling the stories of people who really need to be seen and heard.

You can support our work by donating today.

Amount

Make It Monthly

Don't Miss a Video!

Access our exclusive reporting and rapid response actions directly in your inbox, so you don’t miss a beat in the fight for working people nationwide.

Be a part of a community backing up independent journalism with action.

Pharma Giants Launch Legal Blitz to Prevent Medicare Price Negotiations

Medicare buys upwards of 3,500 drugs a year. Four companies declared legal war when they had to negotiate the price for 10 of them.

The pharmaceutical industry launched a barrage of lawsuits to prevent the federal government from negotiating the price of prescription drugs for Medicare patients. Four companies, Astellas, Bristol Myers Squibb, Johnson & Johnson, and Merck, and two lobbying groups have filed lawsuits. “We are going to take this to the fullest,” Merck & Co. CEO Robert Davis said on a recent investor call, “ultimately to the Supreme Court.”

The litigation stems from a provision in the Inflation Reduction Act (IRA)  that allows the government to negotiate the price Medicare will pay for a small number of prescription drugs. Over 800 companies sell nearly 3,500 drugs to Medicare Part D (the prescription drug supplement program) each year. In 2021, the program’s total gross spending reached nearly $216 billion, an increase of 30 percent from just three years before. The IRA would allow the government to start negotiating the price of 10 drugs, doubling and expanding across Medicare by 2029. 

Gross spending does not account for any discounts the manufacturers give to pharmacy benefit managers (which, because of lobbying, the government is not allowed to disclose). However, it provides a fair scope of the money at play. 

Eliquis, a popular blood thinning drug shared between Bristol Myers Squibb and Pfizer, billed the government for $12.5 billion. Xarelto, a blood thinner owned by Johnson and Johnson, combined with Merck’s blockbuster diabetes drug to cost the government around $9 billion. In total, the ten best-selling prescription drugs account for 22 percent of total gross sales. Astellas, the lone plaintiff without a top drug, isn’t doing too badly. It had $4.5 billion in gross sales to Medicare Part D.

Except for America, nearly all developed countries have some price negotiations between the government and the pharmaceutical industry. The lack of negotiation may be a key reason why the US spends nearly double what the rest of the world does on top prescription drugs. The four plaintiffs follow this trend. Each company generates most of its revenue from America. Research suggests that the United States accounts for over two-thirds of the industry’s profits

With these lawsuits, the pharmaceutical industry is launching a full-on assault to ensure it stays that way.

The crux of the companies’ argument is that the negotiations are “tantamount to extortion.” That’s a claim not even the industry’s supporters believe – mostly because the regulation doesn’t force the companies to sell to the government at a lower price. The entire regime is voluntary.  

Erik Gordon, a University of Michigan Business School Professor, was more colorful, telling STAT there are “better odds that Elizabeth Holmes wins Medtech Innovator of the Year than that Merck wins its lawsuit.”

Of course, this doesn’t mean that the lawsuit will quietly go away. The industry has some of the deepest pockets in the world. Astellas, Bristol Myers Squibb, Johnson & Johnson, and Merck combined to generate $41 billion in profit last year. Legal experts believe the industry is pushing a coordinated strategy; with the goal of generating conflicting lower court decisions – appealing upwards until a partisan, corporate-friendly Supreme Court determines the outcome of the case. 

All of this is happening in the wake of what could be a transformative policy. The Congressional Budget Office estimates that negotiations will save Medicare $237 billion over 10 years

That’s great news for patients and society but bad news for pharmaceutical companies – which is why the fight is just getting started.

Related Stories

YouTube Thumbnail
How One Drug Could Break America’s Health Care System
Read More
Pharma & Crypto Among Winners as Revolving Door Spins From Congress
Read More

The Latest

YouTube Thumbnail
Whistleblower Exposes Toxic Culture At Rivian
Read More
YouTube Thumbnail
Elizabeth Warren Warns of National Abortion Ban if GOP Wins in 2024
Read More
YouTube Thumbnail
What Liberals Get Wrong About Trump Voters
Read More
YouTube Thumbnail
Legal Weed Is Being Ruined By Corporate Greed
Read More
YouTube Thumbnail
Why Going to the Pharmacy Sucks Now
Read More
YouTube Thumbnail
5 Questions with AOC: Trump, Child Labor, Worker Uprisings
Read More
YouTube Thumbnail
I build cars for a living and I can’t afford to buy one.
Read More
YouTube Thumbnail
The End of Overdraft Fees Is Finally Happening
Read More
YouTube Thumbnail
This Lawsuit Could Bring Down Big Oil
Read More
YouTube Thumbnail
Why Waffle House Thrives On Violence
Read More
YouTube Thumbnail
Who is the most anti-worker presidential candidate? Nikki Haley
Read More
YouTube Thumbnail
Corporations Are Privatizing Nursing Homes. The Consequences Are Deadly.
Read More
YouTube Thumbnail
What Honda Doesn’t Want You To Know
Read More
YouTube Thumbnail
The NFL Is Choosing Concerts Over Player Safety. It’s Ending Careers.
Read More
YouTube Thumbnail
Grocery Prices Keep Rising. This Could Stop It.
Read More
YouTube Thumbnail
This Blue Bird Union Victory Could Transform the South
Read More
YouTube Thumbnail
How Harvard University Got Rich
Read More
YouTube Thumbnail
What Solar Companies Don’t Want You To Know
Read More
YouTube Thumbnail
We Exposed The Defense Industry’s Biggest Lie
Read More
YouTube Thumbnail
How Uber Robs Its Drivers
Read More